Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach
Open Forum Infectious Diseases,
Journal Year:
2024,
Volume and Issue:
11(9)
Published: Aug. 27, 2024
Abstract
While
the
acute
manifestations
of
infectious
diseases
are
well
known,
in
some
individuals,
symptoms
can
either
persist
or
appear
after
period.
Postviral
fatigue
syndromes
recognized
with
other
viral
infections
and
described
coronavirus
disease
2019
(COVID-19).
We
have
a
growing
number
individuals
that
for
weeks,
months,
years.
Here,
we
share
evidence
regarding
abnormalities
associated
postacute
sequelae
COVID-19
(PASC)
therapeutics.
describe
physiological
biochemical
seen
reporting
PASC.
several
evidence-based
interventions
to
offer
patients.
It
is
expected
this
understanding
mechanisms
driving
PASC
benefits
certain
therapeutics
may
not
only
lead
better
outcomes
those
but
also
potential
treating
postinfectious
sequelae.
Language: Английский
Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network
BioDrugs,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 29, 2025
Psoriatic
arthritis
(PsA)
is
a
common
comorbidity
in
patients
with
psoriasis
(PsO)
that
leads
to
significant
disease
burden.
Biologic
therapies
targeting
the
interleukin
(IL)-23/IL-17
axis
have
been
widely
used
for
PsO,
but
their
comparative
effectiveness
preventing
PsA
remains
unclear.
The
study
objective
was
compare
occurrence
of
developing
incidental
among
PsO
treated
interleukin-23
inhibitors
(IL23is)
or
interleukin-17
(IL17is).
A
retrospective
cohort
conducted
using
real-world
data
from
TriNetX
US
Collaborative
Network,
including
53
healthcare
organizations.
Adult
IL23is
IL17is
between
January
2019
and
June
2022
were
identified.
Cox
regression
analysis
assess
risk
incidence,
hazard
ratios
(HRs)
95%
confidence
intervals
(CIs)
reported.
Subgroup
analyses
performed
based
on
age,
sex,
ethnicity.
Sensitivity
included
comparisons
tumor
necrosis
factor
(TNF)
(TNFis)
ensure
robustness.
total
4,580
study,
2,273
receiving
2,307
IL17is.
Treatment
associated
significantly
lower
incidence
compared
(HR
=
0.60,
CI
0.44–0.82,
P
0.001).
This
reduction
particularly
notable
41-
65-year
age
group
0.42,
0.27–0.64,
<
0.001)
females
0.57,
0.38–0.86,
0.007).
ethnicity
revealed
varying
outcomes,
White
showing
0.55,
0.38–0.79,
no
observed
Black
African
American
1.37,
0.37–5.13,
0.637).
comparing
TNFis
confirmed
robustness
findings.
are
patients,
specific
ethnic
groups.
These
findings
suggest
may
be
more
suitable
at
high
could
inform
potential
updates
treatment
guidelines.
Further
research
should
focus
refining
therapeutic
strategies
by
incorporating
patient-specific
factors
such
as
comorbidities,
ethnicity,
genetic
predispositions,
which
optimize
biologic
selection
enhance
prevention
efforts
clinical
practice.
Language: Английский
Psoriasis increases the risk of Sjögren’s syndrome: evidence from a propensity score-matched cohort study and transcriptomic analysis
Zijian Kang,
No information about this author
Yu Du,
No information about this author
Ran Cui
No information about this author
et al.
BMC Medicine,
Journal Year:
2025,
Volume and Issue:
23(1)
Published: Jan. 21, 2025
Despite
the
well-documented
immune
dysregulation
in
both
psoriasis
and
Sjögren's
syndrome
(SS),
specific
link
between
these
two
autoimmune
diseases
has
not
been
extensively
explored.
The
present
study
aims
to
investigate
impact
of
on
risk
SS.
A
retrospective
cohort
using
TriNetX
data
compared
SS
development
patients
with
controls
propensity
score
matching,
Kaplan–Meier
curves,
Cox
models.
Transcriptome
were
analyzed
identify
shared
differentially
expressed
genes
pathways
diseases.
total
293,905
an
equal
number
individuals
without
included.
After
baseline
characteristics
groups
balanced.
During
follow-up
period,
3339
1937
developed
curves
indicated
a
significantly
higher
developing
group
non-psoriasis
group.
Upon
adjustment
for
multiple
confounding
factors,
was
50%
than
(hazard
ratio
[HR]
1.50,
95%
confidence
interval
[CI]
1.42–1.58).
Subgroup
analyses
confirmed
elevated
associated
psoriasis.
Patients
psoriatic
arthritis
(PsA)
those
treated
biological
agents
had
even
Transcriptomic
analysis
revealed
potential
pathogenesis
involving
cellular
proliferation,
cell
recruitment,
cytokine
secretion,
interferon
response
viral
infections.
Psoriasis
might
increase
SS,
which
is
augmented
by
PsA.
overlapping
immunological
mechanisms
may
underlie
co-occurrence
Language: Английский
Nirmatrelvir-Ritonavir Significantly Reduces Severe COVID-19 Outcomes in Diverse Taiwanese Populations: Comprehensive Evidence from a Large-Scale Longitudinal Cohort Study in Taiwan
Fu‐Der Wang,
No information about this author
Y. W. Chang,
No information about this author
Han-Chuan Chuang
No information about this author
et al.
Journal of Infection and Public Health,
Journal Year:
2025,
Volume and Issue:
unknown, P. 102760 - 102760
Published: March 1, 2025
Nirmatrelvir-Ritonavir
(NR)
has
proven
effective
for
mild
to
moderate
COVID-19
patients
at
risk
of
disease
progression.
Following
its
emergency
use
authorization
in
Taiwan
January
2022,
this
study
aims
evaluate
impact
on
severe
outcomes
across
different
patient
demographics
Taiwan.
We
performed
a
retrospective
analysis
database
that
includes
data
from
three
hospitals
Northern
Patients
with
2022
were
paired
by
propensity
score
matching
based
NR
prescription.
Cox
proportional
hazard
regression
calculated
ratios
(HR),
adjusting
confounding
factors.
Subgroup
determined
HRs
characteristics.
Among
95,096
patients,
3329
the
group,
and
12,807
non-NR
group.
users
demonstrated
significantly
better
prevention
outcomes:
intubation
(HR=0.296
[95
%
CI:
0.187-0.469],
p
=
0.0482);
ICU
admission
(HR=0.327[0.108-0.991],
<
0.001);
mortality
(HR=0.195
[0.101-0.378],
0.001).
revealed
lower
risks
among
both
sexes,
aged
18-65
or
≥
65
years,
BMI
30,
diabetes
mellitus
(DM),
cardiovascular
(CVD),
chronic
obstructive
pulmonary
(COPD).
was
males,
30.
Mortality
DM,
CVD,
COPD.
reduces
COVID-19,
particularly
older
adults
those
pre-existing
conditions,
supporting
as
an
essential
treatment
high-risk
patients.
Language: Английский
Long‐Term Stroke and Mortality Risk Reduction Associated With Acute‐Phase Paxlovid Use in Mild‐to‐Moderate COVID‐19
Journal of Medical Virology,
Journal Year:
2025,
Volume and Issue:
97(4)
Published: April 1, 2025
ABSTRACT
This
retrospective
cohort
study
investigated
whether
Paxlovid
(nirmatrelvir/ritonavir)
use
during
the
acute
phase
of
mild‐to‐moderate
COVID‐19
reduces
risk
ischemic
or
hemorrhagic
stroke
occurring
more
than
3
months
post‐diagnosis,
a
condition
classified
as
long
COVID.
Utilizing
TriNetX
electronic
health
records
comprising
118
million
patients
in
United
States,
adults
aged
18
years
older
with
confirmed
diagnoses
from
2022
to
2023
were
categorized
into
(administered
within
5
days
diagnosis)
and
non‐Paxlovid
groups.
Exclusion
criteria
included
prior
cerebrovascular
disease,
mortality
months,
specific
antivirals,
severe
clinical
conditions
such
ICU
admission,
intubation,
mechanical
support,
SpO₂
<
90%,
respiratory
rate
>
30/min,
sepsis,
systemic
inflammatory
response
syndrome,
distress
syndrome.
The
index
date
was
initial
diagnosis.
Propensity
score
matching
1:1
ratio
controlled
for
confounding
factors,
(ischemic
hemorrhagic)
analyzed
using
Kaplan–Meier
survival
curves
Cox
proportional
hazards
models.
Among
181
992
matched
pairs,
associated
significantly
reduced
(hazard
[HR]
0.85;
95%
confidence
interval
[CI]:
0.80–0.89)
all‐cause
(HR
0.68;
CI:
0.63–0.73)
COVID
period,
defined
90
post‐diagnosis.
Subgroup
analyses
demonstrated
consistent
protective
effects
across
age,
sex,
BMI,
comorbidities
hypertension,
diabetes,
hyperlipidemia,
vaccination
status.
Notably,
0.81;
0.76–0.86)
individuals
metabolic
conditions,
including
obesity
0.86;
0.78–0.96),
exhibited
pronounced
benefits,
observed
irrespective
These
findings
highlight
that
long‐term
events
mortality,
emphasizing
its
critical
role
mitigating
complications
COVID‐19.
Language: Английский
Clinical Benefits of Sustained Oral Nirmatrelvir/Ritonavir Use for the Outpatient Treatment of COVID-19: Findings from the Taiwanese Health Authority Perspective Using a Decision Tree Modeling Approach
Matthew Sussman,
No information about this author
Jennifer Benner,
No information about this author
Tendai Mugwagwa
No information about this author
et al.
Journal of Market Access & Health Policy,
Journal Year:
2024,
Volume and Issue:
12(4), P. 326 - 341
Published: Nov. 12, 2024
Despite
the
observed
clinical
benefits
of
nirmatrelvir/ritonavir
(NMV/r),
it
is
uncertain
whether
Taiwan
will
continue
covering
NMV/r
for
high-risk
individuals
with
mild-to-moderate
coronavirus
disease
2019
(COVID-19).
This
analysis
assessed
impact
sustained
utilization
on
COVID-19-associated
healthcare
resource
(HCRU)
and
mortality
from
Taiwanese
health
authority
perspective
(THAP).
A
decision
tree
model
estimated
incremental
number
events
associated
over
a
30-day
period.
Model
results
compared
(1)
base
case
using
current
rates
THAP,
(2)
hypothetical
scenario
assuming
supply
not
extended
in
Taiwan.
included
80%
0%
scenario,
respectively.
Outcomes
hospitalizations
involving
general
ward
(GW)
stay,
intensive
care
unit
(ICU)
mechanical
ventilation
(MV)
use,
as
well
bed
days,
symptom
hospitalization
deaths.
Based
epidemiologic
data,
150,255
patients
COVID-19
were
eligible
treatment
THAP.
In
HCRU
increased
by
175%
to
case,
including
increases
GW,
ICU,
MV
use
(differences:
2067;
623;
591,
respectively),
days
(difference:
51,521),
51,714),
deaths
480).
Findings
indicate
that
THAP
reduces
burden
through
reduced
incidence
COVID-19-related
Language: Английский